Investigating the Mechanisms of Action of Ketamine in Depression: Personality Traits, Genetic Polymorphisms, and Epigenetic Changes of Selected Genes in the Serotonergic and Glutaminergic Pathway

This research aims to investigate how ketamine-assisted psychotherapy (KAP) affects specific genes in the serotonergic and glutaminergic pathways among Major Depressive Disorder (MDD) patients. We seek to understand whether the positive outcomes of psychedelic therapies, like ketamine, are linked to changes in gene expression. Using buccal swabs and methylation assessments, we will explore the connections between early-life stress, personality traits, and DNA methylation. The Childhood Trauma Questionnaire (CTQ) and Revised NEO Personality Inventory will gauge stress and personality traits, while the Beck Depression Inventory-II (BDI-II) will measure therapy responses. We anticipate that high questionnaire scores will correlate with increased DNA methylation in specific genes. This research enhances our comprehension of depression development and treatment, benefiting patients and the mental health field. The project will provide valuable insights to Ottawa clinics specializing in psychedelic therapy, allowing them to develop more precise and effective interventions, ultimately improving personalized care for depression sufferers.

Faculty Supervisor:

Monnica T. Williams

Student:

Partner:

Canadian Centre for Psychedelic Healing;Mario Nucci Medicine Professional Corporation

Discipline:

Sociology

Sector:

Health and Related Sciences & Technology

University:

University of Ottawa

Program: